Heather Mason-Suares, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Noonan Syndrome | 6 | 2020 | 120 | 1.990 |
Why?
|
| Infertility, Male | 2 | 2023 | 396 | 1.250 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 3 | 2018 | 223 | 1.210 |
Why?
|
| Cytogenetic Analysis | 2 | 2020 | 270 | 0.790 |
Why?
|
| SOS1 Protein | 2 | 2018 | 40 | 0.750 |
Why?
|
| Sex Chromosome Disorders of Sex Development | 1 | 2020 | 4 | 0.730 |
Why?
|
| Genetic Testing | 4 | 2020 | 3538 | 0.670 |
Why?
|
| Deafness | 1 | 2023 | 459 | 0.640 |
Why?
|
| Neurofibromin 1 | 1 | 2020 | 190 | 0.620 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2020 | 3638 | 0.600 |
Why?
|
| Abortion, Spontaneous | 2 | 2022 | 533 | 0.600 |
Why?
|
| ras Proteins | 2 | 2020 | 1053 | 0.580 |
Why?
|
| Leukemia, Myelomonocytic, Juvenile | 1 | 2017 | 25 | 0.560 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 781 | 0.550 |
Why?
|
| GTP Phosphohydrolases | 2 | 2017 | 516 | 0.540 |
Why?
|
| DNA Copy Number Variations | 4 | 2023 | 2020 | 0.510 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 560 | 0.480 |
Why?
|
| Genome, Human | 5 | 2019 | 4423 | 0.450 |
Why?
|
| Sequence Analysis, DNA | 5 | 2020 | 4740 | 0.430 |
Why?
|
| Peptide Initiation Factors | 1 | 2013 | 55 | 0.430 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2020 | 829 | 0.430 |
Why?
|
| Germ-Line Mutation | 3 | 2018 | 1858 | 0.410 |
Why?
|
| Prenatal Care | 1 | 2019 | 1139 | 0.390 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 473 | 0.390 |
Why?
|
| Chromosome Aberrations | 4 | 2022 | 1771 | 0.370 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 2052 | 0.370 |
Why?
|
| Loss of Heterozygosity | 1 | 2013 | 662 | 0.360 |
Why?
|
| Microarray Analysis | 2 | 2023 | 748 | 0.340 |
Why?
|
| Androgen-Insensitivity Syndrome | 5 | 2006 | 33 | 0.340 |
Why?
|
| Karyotyping | 2 | 2022 | 1171 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2897 | 0.330 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2018 | 1313 | 0.320 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2018 | 1755 | 0.320 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2016 | 3777 | 0.310 |
Why?
|
| Gene Silencing | 1 | 2013 | 1509 | 0.270 |
Why?
|
| Genetic Variation | 4 | 2019 | 6571 | 0.270 |
Why?
|
| Drosophila melanogaster | 1 | 2013 | 1711 | 0.220 |
Why?
|
| Drosophila Proteins | 1 | 2013 | 1699 | 0.220 |
Why?
|
| Receptors, Androgen | 5 | 2006 | 1078 | 0.210 |
Why?
|
| Membrane Proteins | 2 | 2017 | 7852 | 0.210 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2870 | 0.210 |
Why?
|
| Turner Syndrome | 1 | 2022 | 130 | 0.190 |
Why?
|
| Genomics | 5 | 2021 | 5817 | 0.180 |
Why?
|
| Vinculin | 1 | 2020 | 59 | 0.180 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2020 | 116 | 0.180 |
Why?
|
| Chromosomes, Human, Y | 1 | 2020 | 161 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2020 | 17872 | 0.160 |
Why?
|
| Sequence Deletion | 3 | 2015 | 1494 | 0.150 |
Why?
|
| Pregnancy | 5 | 2022 | 29858 | 0.150 |
Why?
|
| Usher Syndromes | 1 | 2018 | 56 | 0.150 |
Why?
|
| Retinopathy of Prematurity | 1 | 2022 | 439 | 0.140 |
Why?
|
| Mosaicism | 1 | 2020 | 475 | 0.140 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2023 | 1650 | 0.130 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2020 | 380 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2016 | 204 | 0.130 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 1 | 2017 | 162 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2020 | 1387 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 641 | 0.120 |
Why?
|
| Biological Specimen Banks | 2 | 2018 | 783 | 0.120 |
Why?
|
| Mutation | 7 | 2021 | 30044 | 0.120 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2020 | 395 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2016 | 15879 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2016 | 331 | 0.120 |
Why?
|
| Genes, BRCA2 | 1 | 2017 | 601 | 0.120 |
Why?
|
| Genes, ras | 1 | 2017 | 653 | 0.120 |
Why?
|
| Cardiomegaly | 1 | 2017 | 591 | 0.110 |
Why?
|
| Infant | 5 | 2020 | 36202 | 0.110 |
Why?
|
| Connexins | 1 | 2015 | 352 | 0.110 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2018 | 828 | 0.110 |
Why?
|
| Genes, BRCA1 | 1 | 2017 | 764 | 0.110 |
Why?
|
| Humans | 34 | 2023 | 761326 | 0.110 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 804 | 0.110 |
Why?
|
| Uniparental Disomy | 1 | 2013 | 45 | 0.110 |
Why?
|
| Consensus | 1 | 2022 | 3122 | 0.100 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
| Female | 19 | 2022 | 392485 | 0.100 |
Why?
|
| DNA Probes | 1 | 2013 | 544 | 0.100 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2013 | 1058 | 0.100 |
Why?
|
| Crosses, Genetic | 1 | 2013 | 751 | 0.100 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 1155 | 0.100 |
Why?
|
| Infant, Newborn | 5 | 2022 | 26211 | 0.100 |
Why?
|
| Male | 19 | 2023 | 360621 | 0.100 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2019 | 1555 | 0.090 |
Why?
|
| Disease | 1 | 2016 | 672 | 0.090 |
Why?
|
| Neoplasms | 2 | 2017 | 22158 | 0.090 |
Why?
|
| Consanguinity | 1 | 2013 | 456 | 0.090 |
Why?
|
| Multifactorial Inheritance | 1 | 2019 | 1392 | 0.090 |
Why?
|
| Databases, Genetic | 1 | 2017 | 1738 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 4286 | 0.080 |
Why?
|
| Prenatal Diagnosis | 1 | 2016 | 1265 | 0.080 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2016 | 942 | 0.080 |
Why?
|
| Body Weight | 1 | 2019 | 4614 | 0.080 |
Why?
|
| Cardiomyopathies | 1 | 2020 | 1964 | 0.080 |
Why?
|
| Homozygote | 1 | 2013 | 1796 | 0.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2016 | 1742 | 0.080 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4108 | 0.070 |
Why?
|
| Pedigree | 3 | 2020 | 4589 | 0.070 |
Why?
|
| Chromosome Breakpoints | 2 | 2018 | 93 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 3200 | 0.070 |
Why?
|
| Alleles | 2 | 2019 | 6909 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 6086 | 0.070 |
Why?
|
| Genetic Loci | 1 | 2015 | 2628 | 0.070 |
Why?
|
| Electronic Health Records | 3 | 2018 | 4812 | 0.060 |
Why?
|
| Cohort Studies | 4 | 2020 | 41440 | 0.060 |
Why?
|
| Phenotype | 3 | 2022 | 16603 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2020 | 42251 | 0.050 |
Why?
|
| Base Sequence | 1 | 2013 | 12449 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 5778 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 58946 | 0.050 |
Why?
|
| Middle Aged | 10 | 2020 | 220774 | 0.050 |
Why?
|
| Protein Binding | 1 | 2013 | 9351 | 0.040 |
Why?
|
| Gene Frequency | 2 | 2018 | 3639 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 17640 | 0.040 |
Why?
|
| Adolescent | 5 | 2020 | 88305 | 0.040 |
Why?
|
| Child | 4 | 2020 | 80156 | 0.040 |
Why?
|
| Costello Syndrome | 1 | 2018 | 19 | 0.040 |
Why?
|
| X Chromosome | 1 | 2022 | 816 | 0.040 |
Why?
|
| Failure to Thrive | 1 | 2018 | 140 | 0.040 |
Why?
|
| Facies | 1 | 2018 | 222 | 0.040 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 2724 | 0.040 |
Why?
|
| Ectodermal Dysplasia | 1 | 2018 | 106 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 23981 | 0.040 |
Why?
|
| Amino Acid Substitution | 3 | 2006 | 1737 | 0.040 |
Why?
|
| Penetrance | 1 | 2019 | 388 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2013 | 10431 | 0.040 |
Why?
|
| Pennsylvania | 1 | 2018 | 613 | 0.040 |
Why?
|
| Obesity | 1 | 2019 | 12934 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 2016 | 260 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2016 | 267 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2016 | 198 | 0.030 |
Why?
|
| Introns | 1 | 2018 | 981 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2018 | 23427 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2021 | 7954 | 0.030 |
Why?
|
| Virulence | 1 | 2018 | 1302 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 437 | 0.030 |
Why?
|
| Heterozygote | 1 | 2020 | 2803 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2015 | 628 | 0.030 |
Why?
|
| Mutation, Missense | 3 | 2006 | 2570 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 2749 | 0.030 |
Why?
|
| Hypolipidemic Agents | 1 | 2016 | 609 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2016 | 627 | 0.020 |
Why?
|
| Drug Design | 1 | 2016 | 1050 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 1486 | 0.020 |
Why?
|
| Adult | 7 | 2020 | 221122 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2015 | 1218 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 80575 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2509 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2018 | 1127 | 0.020 |
Why?
|
| Hearing Loss | 1 | 2015 | 783 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2015 | 2667 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2017 | 4280 | 0.020 |
Why?
|
| Young Adult | 3 | 2020 | 59196 | 0.020 |
Why?
|
| Aged | 4 | 2020 | 169179 | 0.020 |
Why?
|
| Lipids | 1 | 2016 | 3341 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 12450 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2811 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 13446 | 0.020 |
Why?
|
| Health Personnel | 1 | 2018 | 3335 | 0.010 |
Why?
|
| Software | 1 | 2018 | 4439 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 14597 | 0.010 |
Why?
|
| Genotype | 1 | 2017 | 12982 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2018 | 4696 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 22124 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2019 | 12949 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15835 | 0.010 |
Why?
|
| Animals | 1 | 2013 | 168388 | 0.010 |
Why?
|
| Prevalence | 1 | 2017 | 15719 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 12666 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 20092 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 26108 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 74152 | 0.010 |
Why?
|
| United States | 1 | 2018 | 72317 | 0.010 |
Why?
|